XENON PHARMACEUTICALS INC. Ttl Fee Amt
XENON PHARMACEUTICALS INC. (XENE) had Ttl Fee Amt of $2.22 thousand as of 2026-04-13, per its S-8 filed 2026-04-13.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-04-13
- 2026-04-13: Ttl Fee Amt $2.22K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-04-13 | $2.22K S-8 · filed 2026-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |